Insider transactions at America's Car-Mart are not encouraging. Modest insider ownership shows some alignment with smaller shareholders, but significant stock sales by insiders could indicate an expected downturn.
Recent share price surges won't negate long-term declines, claim analysts. EPS losses and a three-year downturn prompt a closer look at company's historical growth and fundamentals before investing.
CEO Doug Campbell remains confident in Car-Mart's ability to generate consistent cash flows despite unexpected loss, with hopes that current credit loss situation will be temporary as car prices are likely to normalize in the future.
Car-Mart's acquisition of Central Auto Sales suggests a bright future due to shared goals and superior service. The union could help solidify Car-Mart’s dominance in the car dealership industry while elevating their reconditioning and servicing abilities.
Despite a short-term fall of ROCE at America's Car-Mart, increasing revenue and capital employed might indicate a promising long-term stock performance. Investors seem to acknowledge it, resulting in a 12% gain over the last five years.
The selling of America's Car-Mart shares by insiders, amidst dropping company value, signals caution to investors. Despite some insider buying, a lukewarm insider ownership level calls for cautious investment in the company.
CEO and President Doug Campbell and other executives express deep condolence and appreciation of Mr. Henderson's contributions to CRMT, highlighting his commitment to associates and customers. His demise is likely to affect the morale of the company.
America's Car-Mart Stock Forum
• $Array Technologies (ARRY.US)$ +12.87% (also names new CEO)
• $Tufin Software Technologies (TUFN.US)$ +43.41% (enters into definitive agreement to be acquired by Turn/River Capital in a $570 million transaction; TUFN shareholders will receive $13.00/share in cash)
• $Citius Pharmaceuticals (CTXR.US)$ +10.87% (reported topline results from the pivotal Phase 3 trial of I/ONTAK)
• $BioXcel Therapeutics (BTAI.US)$ +19.22% (FDA ha...
No comment yet